Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatent for advanced or metastatic esophageal squamous cell carcinomas

ZHAO Yingying, JU Wenxiang, ZHANG Xiaohan, LU Luolan, SHEN Aizong

Chinese Journal of Hospital Pharmacy ›› 2025, Vol. 45 ›› Issue (4) : 418-426.

PDF(2145 KB)
PDF(2145 KB)
Chinese Journal of Hospital Pharmacy ›› 2025, Vol. 45 ›› Issue (4) : 418-426. DOI: 10.13286/j.1001-5213.2025.04.08
Drug and Clinical Practice

Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatent for advanced or metastatic esophageal squamous cell carcinomas

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2025, 45(4): 418-426 https://doi.org/10.13286/j.1001-5213.2025.04.08

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(2145 KB)

Accesses

Citation

Detail
Sections
Recommended
Information
Governed by: China Association for Science and Technology
Sponsored by: Chinese Pharmaceutical Association
Published by: Editorial Office of Chinese Journal of Hospital Pharmacy
ISSN 1001-5213
CN 42-1204/R
Contact
Website Copyright © Chinese Journal of Hospital Pharmacy, All Rights Reserved.
Tel: 027-82836596
E-mail：pharmacy@vip.163.com
Wechat

/

〈 〉